---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-026275"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2026-08-06T20:16:26+00:00"
generated_at: "2026-08-06T20:20:10.882551+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Phio Pharma Q2 net loss $4.1M; cash $13.0M; PH-762 Phase 1b completed

## Summary
- Net loss of $4.1M for Q2 2026 vs $2.2M in Q2 2025, driven by higher R&D spend.
- Cash and equivalents $13.0M at June 30, 2026, down from $21.0M at Dec 31, 2025.
- R&D expenses $3.1M in Q2, up 187% YoY on nonclinical toxicology and CMC costs.
- Phase 1b trial of PH-762 completed; FDA meeting requested in Q3 2026 for next steps.
- Established ATM equity offering up to $6.36M in April 2026.

## SEC filing metadata
- accession: 0001437749-26-026275
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2026-08-06T20:16:26+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774926026275/0001437749-26-026275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774926026275/phio20260519_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-026275
- JSON: https://secwatch.observer/filing/0001437749-26-026275.json
- Plain text: https://secwatch.observer/filing/0001437749-26-026275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.